Tags: clinical trial + study.with.MS

Sort by: Date / Title / URL

1. Preclinical Studies Suggest FTY720 Mechanisms In Multiple Sclerosis May Include Direct Activity In The Brain
   The data suggest that FTY720 may have the potential to reduce neurodegeneration and enhance repair of the central nervous system (CNS) by modulating S1P receptors expressed on brain cells.
   06-05-2007 to clinical trial, depression, drugs, fingolimod, multiple sclerosis, study by admin
2. Roskamp Institute Looking for Volunteers for Multiple Sclerosis Research Study
   The Roskamp Institute announced today its participation in a pharmaceutical sponsored research study for relapsing-remitting Multiple Sclerosis (MS) sufferers.
   08-12-2006 to clinical trial, drug company, drugs, fingolimod, multiple sclerosis, relapsing remitting, research, rrms, study by admin
3. Opexa begins dosing in trial for multiple sclerosis - Pharmaceutical Business Review
   The phase IIb clinical study will be designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T Cell vaccination with clinically isolated syndrome and relapsing-remitting multiple sclerosis patients.
   08-11-2006 to clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, rrms, study, tovaxin by admin
4. New data for FTY720 - aiming to become the first orally effective multiple sclerosis treatment - show sustained benefits over two years
   The developmental oral therapy FTY720 (fingolimod) has demonstrated sustained benefits over two years in patients suffering from relapsing multiple sclerosis (MS), indicating that it could provide an important new option for treating this disabling neurol
   29-09-2006 to clinical trial, drugs, fingolimod, multiple sclerosis, research, study, treatment by admin
5. Rituxan is effective in relapsing-remitting multiple sclerosis
   The study of 104 patients showed a statistically significant reduction in the total number of gadolinium enhancing T1 lesions observed on serial MRI scans of the brain at weeks 12, 16, 20 and 24 in the Rituxan-treated group compared to placebo
   29-09-2006 to clinical trial, multiple sclerosis, relapsing remitting, research, rituxan, rrms, study, treatment by admin
6. Clinical Trial: Extension Study to Evaluate Safety, Tolerability and Effects on Efficacy Parameters of FTY720 in Patients With Relapsing Multiple Sclerosis.
   This study will evaluate the long-term safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.
   14-09-2006 to clinical trial, drugs, fingolimod, multiple sclerosis, relapsing remitting, research, rrms, study by admin
7. NEJM -- Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
   In this proof-of-concept study, fingolimod reduced the number of lesions detected on MRI and clinical disease activity in patients with multiple sclerosis. Evaluation in larger, longer-term studies is warranted.
   14-09-2006 to clinical trial, drugs, fingolimod, multiple sclerosis, research, study, treatment by admin
8. Campath showing potential to treat multiple sclerosis - San Antonio Business Journal:
   Data analyzed after two years showed a 75 percent reduction in the risk of relapse for patients taking Campath compared to patients treated with Rebif, Genzyme says.
   14-09-2006 to campath, clinical trial, drug company, drugs, multiple sclerosis, rebif, research, study, treatment by admin
9. Genentech, Biogen say cancer drug helps against MS | Health | Reuters.co.uk
   Biotechnology companies Genentech Inc. and Biogen Idec Inc. on Monday said their cancer drug Rituxan showed hints of effectiveness against multiple sclerosis in a small mid-stage trial
   28-08-2006 to canada, chemotherapy, clinical trial, drug company, drugs, multiple sclerosis, research, rituxan, study, treatment, us by admin
10. Clinical Trial: Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
    The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treatment of R-R MS.
    07-08-2006 to clinical trial, copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, relapsing remitting, research, rrms, study by admin
11. Teva Initiates Phase III Study To Confirm Increased Efficacy Of Higher Dose Of Glatiramer Acetate For Relapsing-Remitting Multiple Sclerosis
    Teva Pharmaceutical Industries Ltd. announced the initiation of a large Phase III study designed to confirm the positive results from the Phase II study which compared a new higher dose of 40 mg/day dose of glatiramer acetate (GA) to the currently approve
    07-08-2006 to clinical trial, copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, relapsing remitting, research, rrms, study, treatment by admin
12. Clinical Trial: Safety and Efficacy of Pravastatin in Relapsing-Remitting Multiple Sclerosis
    in an open labeled human study in MS, statin regimen was associated with a decreased lesional activity asessed by MRI. Statins are well tolerated drugs, used for many years, with a low cost and with a putative efficacy in MS.
    30-07-2006 to clinical trial, drugs, pravastatin, relapsing remitting, research, rrms, study by admin
13. Clinical Trial: Efficacy and Safety of Fingolimod in Patients With Relapsing-Remitting Multiple Sclerosis
    This study will assess safety, tolerability and effects on efficacy parameters of fingolimod administered orally to patients with relapsing-remitting multiple sclerosis.
    29-07-2006 to clinical trial, drugs, multiple sclerosis, relapsing remitting, research, rrms, study by admin
14. Multiple Sclerosis Quarterly Report » Blog Archive » MS Medications in the Pipeline
    Here we describe many of the new medications and treatment approaches that are already being tested in clinical studies
    22-07-2006 to avonex, clinical trial, copaxone, drugs, glatiramer acetate, interferon, mbp8298, mitoxantrone, multiple sclerosis, research, study, treatment, tysabri by admin
15. United Kingdom early Mitoxantrone Copaxone trial
    The United Kingdom early Mitoxantrone Copaxone trial is a controlled study which will compare combination therapy with mitoxantrone and Glatiramer Acetate (Copaxone) against high dose interferon beta treatment (Rebif 44).
    21-07-2006 to clinical trial, copaxone, drugs, glatiramer acetate, mitoxantrone, multiple sclerosis, relapsing remitting, research, rrms, study, treatment, uk by admin

First / Previous / Next / Last / Page 1 of 2